Compare SoFi Technologies Inc (SOFI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs Twist Bioscience Corp — how do they compare? SoFi Technologies Inc trades at $15.74 (market cap $20.23B), while Twist Bioscience Corp trades at $157.47 (market cap $10.32B). The key difference: SoFi Technologies Inc is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SoFi Technologies Inc for 60 Days and Twist Bioscience Corp for 27 Days on average.
| SOFI | TWST | |
|---|---|---|
Market Cap | $20.23B | $10.32B |
Volume | 32,692,405 | 5,894,998 |
Sector | Financials | Health |
52-Week High | $32.21 | $205.00 |
52-Week Low | $15.15 | $25.45 |
Typical Hold Time | 60 Days | 27 Days |
Enterprise Value | $20.37B | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOFI Technologies stock trades at $15.66, down 0.64% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue has grown from $1.6B in 2022 to $3.6B in 2025, though net income margins have fluctuated. Analyst consensus is a Buy with a $21.58 price target, but technical indicators suggest near-term pressure.
The outlook for SOFI is mixed: strong fundamentals and growth potential are offset by technical weakness and competitive risks. Investment opportunity lies in its revenue trajectory and market position, but investors face risks from execution challenges and interest rate sensitivity. The stock's current valuation metrics indicate premium pricing relative to peers, requiring careful monitoring of upcoming earnings.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
